TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06378567

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement liquid shot beverage products
Description: Participants will use their product as instructed for 3 of the 4 study weeks
Study: NCT06729918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulated patient
Description: Thoracic lung physical examination will be studied using a simulated patient.
Study: NCT06378567

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement liquid shot beverage products
Description: Participants will use their product as instructed for 3 of the 4 study weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement liquid shot beverage products
Description: Participants will use their product as instructed for 3 of the 4 study weeks
Study: NCT06401395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIGIPARK MONITOR
Description: remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
Study: NCT05563233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helfer skin tap technique
Description: Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shot Blocker
Description: Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
Study: NCT06748001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib will be administered in accordance with the parent study protocol.
Study: NCT06753565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnitine
Description: It is a nutritional supplement with trade name  Carnitol® in Egypt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disease-modifying anti-rheumatic drugs
Description: They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Disease-modifying anti-rheumatic drugs
Description: They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
Study: NCT06755554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of Indocyanine green
Description: ICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.
Study: NCT06758323

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice combined with caffeine (COM)
Description: * 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session~* 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice placebo with caffeine (CAF)
Description: - 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice with caffeine placebo (BRJ)
Description: - 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
Study: NCT06030791

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of operated knee

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of operated knee
Study: NCT06758323

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot placebo with caffeine placebo (PLA)
Description: - 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
Study: NCT06757413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Virtual reality
Description: This study evaluates a 4-week multidisciplinary intervention for patients with chronic non-specific low back pain, combining physiotherapy and psychological approaches. Both components leverage virtual reality (VR) technology to address physical and psychological aspects of pain management, operating in parallel to maximize patient outcomes. The physiotherapy intervention consists of a therapeutic exercise program based on the principles of the Back School. Over 8 sessions (2 per week), patients perform VR-guided exercises where visual-proprioceptive information is manipulated.~The psychological positive body image-based intervention consists of 4 sessions approaching 5 different clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. 2 sessions (Body Awareness and Pain Acceptancce) will include virtual reality environments to enhance the clinical outcomes.
Study: NCT04817371

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (e-noses)
Description: VOC analysis in exhaled air with e-noses.

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (e-noses)
Description: VOC analysis in exhaled air with e-noses.
Study: NCT05108363

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification program
Description: Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
Study: NCT06757413

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Treatment as usual
Description: Participants will receive the usual treatment applied at the hospital
Study: NCT06755281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Oral challenge
Description: Patients will receive a 2-step challenge with the suspected penicillin and will be monitored for any allergic reaction within the first four hours. Patients will be contacted around 7 days after the drug provocation test to inquire delayed allergic reactions.
Study: NCT05319041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wei's Qi Ju Gan Lu Formula
Description: The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye.
Study: NCT05378893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR10624 for injection
Description: administered via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR10624 for injection
Description: administered via subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered via subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered via subcutaneous injection
Study: NCT04764838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)
Study: NCT06755281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: The patient will receive skin prick test and patch test (if a delayed allergy is suspected). Allergen-specific IgE will be measured. If all negative, drug provocation tets will be performed identical to the experimental group.
Study: NCT06757543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Description: Video laryngoscopy with C-MAC (Karl Storz, Tuttlingen, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy with standard laryngoscope
Description: Direct laryngoscopy with standard laryngoscope
Study: NCT06757985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a clinically guided resuscitation protocol,
Description: a clinically guided resuscitation protocol, derived from EGDT and modified to match with the latest survival sepsis campaign guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a transthoracic bedside focused echocardiographic assessment
Description: a transthoracic bedside focused echocardiographic assessment of the patient will be done, as a baseline ECHO in a three-step approach to monitor hemodynamics using Logiq P7, S5-1 ECHO probe;
Study: NCT06756438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study product
Description: Anti-itching, anti-replapse and repairing treatment. Emollient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Emollient
Study: NCT04817371

Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.

Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.

Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.

Intervention type: OTHER
Group type: OTHER
Intervention: Canine odor detection of Volatile Organic Compounds
Description: VOC analysis in sweat by trained dogs.
Study: NCT06759272

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided antiplatelet therapy
Description: A panel of genes including CYP2C19\*2 (rs4244285) and CYP2C19\*3 (rs4986893) will be genotyped using the real-time PCR and the expected turnover time will be 48 hours. Patients who are identified to have reduced function CYP2C19 allele will receive 90 mg ticagrelor and patients with wild-type CYP2C19 allele will receive clopidogrel 75 mg in the next scheduled dose. The switching done from clopidogrel to ticagrelor is supported by Antiplatelet Therapy Switching Clinician Guideline, whereby in the maintenance or low risk phase, there is generally no need to administer a loading dose of ticagrelor; one can switch directly to ticagrelor maintenance dose 24 hours after the last dose of clopidogrel
Study: NCT06761937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Description: Thermotherapy will be given once a week after a radiotherapy fraction
Study: NCT04817371

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (mass spectrometry)
Description: VOC analysis in exhaled air with mass spectrometry.
Study: NCT06761937

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard radiotherapy
Description: standard radiotherapy
Study: NCT06762275

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic strategy
Description: GPs' use of an externally validated cPR followed by CRP-POCT in the medium risk group. See for details: Detailed description - Intervention.
Study: NCT04817371

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (mass spectrometry)
Description: VOC analysis in exhaled air with mass spectrometry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (mass spectrometry)
Description: VOC analysis in exhaled air with mass spectrometry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis (mass spectrometry)
Description: VOC analysis in exhaled air with mass spectrometry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis in sweat (mass spectrometry)
Description: VOC analysis in sweat with mass spectrometry.
Study: NCT06762015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Nursing Practice Environments Promotion Program
Description: A multi-component intervention program aimed at promoting positive nursing practice environments.
Study: NCT06762106

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: solid unite made with metal frame and case

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hot back
Description: thermal hot back
Study: NCT06761014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental assisted soft tissue mobilization
Description: instrument will be held at 45° angle and the IASTM treatment will be administered for about 20 seconds in a direction parallel to the muscle fibers being treated with deep strokes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained stretching
Description: The therapist will apply the pressure or ask to maintain the stretch. A total of thirty seconds, divided into three sets of stretches at each intervention, with ten seconds of rest in between
Study: NCT06760988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CL22205
Description: Experimental Dose: 200 mg, Mode: Oral, once daily after breakfast Duration: 135 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mode: Oral, once daily after breakfast Duration: 135 days
Study: NCT06762223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin 10 mg daily
Description: Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai Hengrui Pharmaceutical Co., Ltd (China). It received marketing authorization in China on December 31, 2021 (ID: H20210053).The prescribed dosage of Henagliflozin is 10 mg per day, as indicated on the drug label, with administration recommended in the early morning. In instances where a participant forgot to take the medication in the morning, they were permitted to do so until 12:00 PM on the same day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1700 mg daily
Description: The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg daily
Description: The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.
Study: NCT04817371

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis in sweat (mass spectrometry)
Description: VOC analysis in sweat with mass spectrometry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis in sweat (mass spectrometry)
Description: VOC analysis in sweat with mass spectrometry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Volatile Organic Compounds analysis in sweat (mass spectrometry)
Description: VOC analysis in sweat with mass spectrometry.
Study: NCT05319041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5g maltodextrin without any herbs medicine
Study: NCT06440213

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeptiControl™ (Low - Dose 435 mg/day)
Description: Plant protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeptiControl™ (Mid - Dose 870 mg/day)
Description: Plant protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeptiControl™ (High - Dose 2610 mg/day)
Description: Plant protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Microcrystalline Cellulose
Description: Placebo MCC micro-crystalline cellulose
Study: NCT06762223

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Henagliflozin
Description: The placebo was supplied by the pharmaceutical company responsible for Henagliflozin, ensuring that both the placebo and Henagliflozin were indistinguishable in terms of appearance, taste, and odor, while lacking any significant pharmacological effect. Administration of the placebo was recommended to occur in the early morning.
Study: NCT06762314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.
Study: NCT04921709

Intervention type: OTHER
Intervention: Medical tests
Description: Blood tests

Intervention type: OTHER
Intervention: Medical tests
Description: Blood tests
Study: NCT06475079

Intervention type: OTHER
Intervention: • FHP app (Pyeongtaek, South Korea) mobile application
Description: FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle

Intervention type: OTHER
Intervention: • FHP app (Pyeongtaek, South Korea) mobile application
Description: FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle
Study: NCT06319196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdualag
Description: Opdualag vial IV every 4 weeks (Q4W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 480mg IV Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg IV Q4W
Study: NCT05604989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Combination Cap/Tab
Description: The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus \& Bifidobacterium lactis.
Study: NCT05879380

Intervention type: DIAGNOSTIC_TEST
Intervention: MRPA
Description: patients will receive an extra MRPA, on top of the standard CTPA

Intervention type: DIAGNOSTIC_TEST
Intervention: CPTA
Description: patients will receive an extra MRPA, on top of the standard CTPA
Study: NCT05544110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial magnetic stimulation
Description: The coil parallel to the scalp is placed on the target for real and effective stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
Study: NCT05452187

Intervention type: DRUG
Intervention: Assess the effectiveness and safety of DAAs in patients with IBD.
Description: Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).

Intervention type: DRUG
Intervention: Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.
Description: Variables evaluated: Interactions.

Intervention type: OTHER
Intervention: Assessment of the impact of DAAs on the course of IBD.
Description: Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of \<0.05.
Study: NCT05044715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy (CFT)
Description: The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.